[Retracted] The RPL4P4 Pseudogene Is a Prognostic Biomarker and Is Associated with Immune Infiltration in Glioma

Table 1

The correlation between RPL4P4 and clinicopathological characteristic in TCGA-glioma dataset.

Characteristic	Low expression of RPL4P4	High expression of RPL4P4
	348	348
WHO grade, (%)			<0.001
G2	144 (22.7%)	80 (12.6%)
G3	166 (26.1%)	77 (12.1%)
G4	0 (0%)	168 (26.5%)
IDH status, (%)			<0.001
WT	92 (13.4%)	154 (22.4%)
Mut	255 (37.2%)	185 (27%)
1p/19q codeletion, (%)			0.842
Codel	88 (12.8%)	83 (12%)
Noncodel	260 (37.7%)	258 (37.4%)
Primary therapy outcome, (%)			0.142
PD	77 (16.7%)	35 (7.6%)
SD	95 (20.6%)	52 (11.3%)
PR	44 (9.5%)	20 (4.3%)
CR	78 (16.9%)	61 (13.2%)
Histological type, (%)			<0.001
Astrocytoma	139 (20%)	56 (8%)
Glioblastoma	0 (0%)	168 (24.1%)
Oligoastrocytoma	83 (11.9%)	51 (7.3%)
Oligodendroglioma	126 (18.1%)	73 (10.5%)
Age, n (%)			<0.001
≤60	300 (43.1%)	253 (36.4%)
>60	48 (6.9%)	95 (13.6%)